Cell line · CVCL_2078
Papers56
1 to 20 of 56
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-myeloma activity of the CXCR4 antagonist WZ811. | J Mol Med (Berl) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. | Blood Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. | Blood Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma. | Haematologica | 2025 | Its Methods give the RRID and name the line | PubMed | |
| High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma. | Biomolecules | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Functional Investigation of IGF1R Mutations in Multiple Myeloma. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma. | Cancer Immunol Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. | Neoplasia | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2078/papers